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2. Materials and methods 
Abstract A macrophage migration inhibitory factor (MIF), 
originally described as a product of activated lymphocytes, has 
been defined as a 12 kDa protein, expressed in a wide variety of 
tissues. Here MIF is identified as a phenylpyruvate tautomerase 
(EC 5.3.2.1) having /»-hydroxyphenylpyruvate and phenylpyr-
uvate as its natural substrates. The definition of MIF as an 
enzyme may yield insight into the mechanism of action of this 
proinflammatory and immunomodulating cytokine. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
A macrophage migration inhibitory factor (MIF) was first 
described as a soluble material released from sensitized lym-
phocytes when stimulated by antigen [1,2]. Since the cloning 
of its c D N A [3], M I F has been found to be expressed in a 
large number of tissues [4—12]. More recently M I F has been 
reported to be released from macrophages exposed to low 
concentrations of glucocorticoids. Once secreted, M I F acts 
to counter-regulate the immunosuppressive effects of the glu-
cocorticoids [13,14]. M I F has also been found to potentiate 
endotoxemia, and an t i -MIF antibodies are protective in this 
condition [7]. An unexpected activity of M I F was recently 
discovered in studies of the enzymatic conversion of imino-
chromes to Índoles [15]. A 12 k D a protein, which catalyzes the 
conversion of the non-natural D-isomer of 2-carboxy-2,3-dihy-
droindole-5,6-quinone (D-dopachrome) to 5,6-dihydroxyin-
dole-2-carboxylic acid (DHICA) by a tautomerization reac-
tion, was isolated from the cytosol of the bovine optic lens. 
The first 27 N-terminal amino acids were found to be identical 
with those of bovine M I F . The catalytic activity of isolated 
native M I F was confirmed by studies of purified recombinant 
human M I F which manifested the same tautomerase activity. 
The observation that M I F has a tautomerase activity sug-
gested that it may exert its biological effects by an enzymatic 
reaction. Here we identify M I F as a phenylpyruvate tauto-
merase (EC 5.3.2.1.) with/i-hydroxyphenylpyruvate and phe-
nylpyruvate as natural substrates. 
Corresponding author. Fax: (46) (46) 157887. 
2.1. Isolation and definition of proteins 
MIF was isolated from the bovine lens as previously described [15]. 
SDS-PAGE, immunoblotting, and detection of proteins were per-
formed as described by Finke et al. [16]. MIF-specific monoclonal 
antibody was purchased from R&D Systems. Mass spectrometry of 
recombinant MIF was performed by Professor Ake Engström, De-
partment of Medical and Physiological Chemistry, Uppsala, Sweden. 
Total amino acid content was determined at the amino acid analysis 
unit of the BMC, Uppsala, Sweden. 
2.1.1. Protein blotting and amino acid sequence analysis. After 
SDS-PAGE, using a semi-dry electroblotting apparatus (JKA Biotech, 
Denmark) the proteins were electroblotted to a PVDF membrane 
(Millipore, Bedford, MA, USA) as described by Matsudaira [17], 
The protein band was cut out with a razor and sequenced at the 
Biomolecular Resource Facility (Lund, Sweden), using an ABI 477 
protein/peptide sequencer. 
2.1.2. Chromatofocusing. The proteins were isolated with the 
Pharmacia FPLC system and a prepacked Mono P HR 5/20 column. 
The column was equilibrated with starting buffer (75 mM Tris-HAc, 
pH 9.3). After sample application, the proteins were eluted, using a 50 
ml superloop, with polybuffer 96 (diluted 1:10, pH 6.0) at a flow rate 
of 1.0 ml/min. 
Isoelectric focusing was performed according to a previously de-
scribed method [18]. 
2.2. Human recombinant MIF 
The coding region of the MIF was specifically PCR-amplified from 
a human liver cDNA library, and the PCR fragment was cloned into 
the pKK223-3 prokaryotic expression vector (Pharmacia) and ex-
pressed in IPTG-induced transformed E. coli bacteria. The human 
recombinant MIF used in our studies has the nucleotide sequence 
described by Paralkar and Wistow [19]. 
2.3. Determination of enzymatic activity 
Tautomerase activity was measured in two ways: (1) by ascertain-
ing the rate of DHICA formation from D-dopachrome, as described 
by Aroca et al. [20] ; and (2) by measuring the rate of the formation of 
the enol form from the keto form of ^-hydroxyphenylpyruvate and of 
phenylpyruvate as described by Knox [21,22]. The substrates were 
purchased from Sigma. The rate of the reaction was determined in 
the first 60 s. 
2.4. NMR spectroscopy 
1H nuclear magnetic resonance (NMR) spectra were recorded using 
a Bruker DRX-400 spectrometer. The chemical shifts are given in 
parts per million relative to methanol as internal standard (8 = 3.31 
ppm). The coupling constants are given in Hertz. First-order chemical 
shifts and coupling constants were obtained from one-dimensional 
spectra, and proton resonances were assigned from COSY 
experiments. p-Hydroxyphenylpyruvate (3.5 urnol) was dissolved in 
0.7 ml 50 mM acetate/D20 buffer (pH 6.2). 
2.4.1. 'H NMR (400 MHz, 50 mM acetatelD20 at pH 6.2) of p-
hydroxyphenylpyruvate. Enol form: 8 6.32 (s, H), 6.91 (d, J = 8.6 Hz, 
2H), 7.66 (d, J = 8.6 Hz, 2H). Keto form: 8 3.98 (s,H), 6.88 (d, J = 8.6 
Hz, 2H), 7.13 (d, J = 8.7 Hz, 2H). 
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Fig. 1. The keto-enol tautomerism of ^-hydroxyphenylpyruvate studied by JH NMR. A: Spectrum recorded immediately after dissolving 3.5 
umol /»-hydroxyphenylpyruvate in 0.7 ml 50 mM acetate/D20 buffer (pH 6.2). B: Spectrum of the /»-hydroxyphenylpyruvate solution 15 min 
after the addition of 1 |ig of human recombinant MIF [36]. 
3. Results 
A series of compounds were examined as potential sub-
strates of MIF by analyzing their competitive inhibition of 
the tautomerization of D-dopachrome to DHICA. One of 
the substances tested, /»-hydroxyphenylpyruvate, at a concen-
tration of 1 mM, was found to completely inhibit the forma-
tion of DHICA from D-dopachrome. Assuming that p-hy-
droxyphenylpyruvate might be a substrate, we examined its 
UV spectrum after the addition of MIF and found a rapid 
and pronounced decrease in UV absorption at 300 nm, con-
sistent with tautomerization of the enol form to the keto form. 
The enol form is characterized by strong absorption at about 
300 nm, a wavelength at which absorption of the keto form is 
more than 10 times lower [21]. The MIF-catalyzed tautome-
rization was demonstrated by means of NMR studies (Fig. 1). 
The spectrum recorded immediately after dissolving /»-hydrox-
yphenylpyruvate in acetate buffer at pH 6.2 (Fig. 1A) revealed 
two doublets in the aromatic region and a sharp singlet rep-
resenting an olefinic proton at 5 = 6.32 ppm consistent with 
the enol form. Minor changes were noted after the solution 
was left standing at room temperature for 1 h. Fig. IB shows 
the *H NMR spectrum of the /»-hydroxyphenylpyruvate sol-
ution 15 min after the addition of 1 tig of human recombinant 
MIF. Conversion of the enol to the keto form was demon-
strated by changes in the chemical shifts of the aromatic pro-
tons and by registration of a singlet corresponding to méth-
ylène protons at 6 = 3.98 ppm. A small amount of the 2,2-
dihydroxy derivative of the keto form was indicated by the 
presence of a weak singlet at 5 = 2.98 ppm. 
The kinetic properties of the enzyme were studied using 
spectrophotometry [22]. The tautomerization of /»-hydroxy-
phenylpyruvate was catalyzed by MIF in borate buffer with 
a Km of 2.4 mM, and VmasL of 1.1 mmol/mg-min for the keto 
to enol form reaction, kCSbt/Km 0.92 X 105 M"1 s"1. Phenylpyr-
uvate also functioned as a substrate with a Km of 6.0 mM and 
Fmax of 3.9 mmol/mg-min for tautomerization of the keto 
form to the enol form, kmt/Km 1.3 x10 s M _ 1 s_1. 
Our MIF preparation purified from the bovine lens, exam-
ined by chromatofocusing, was found to occur in two forms 
with p/s of 8.0 and 7.7, as determined by isoelectric focusing. 
Determination of total amino acid content showed the two 
forms to have the same amino acid composition (Table 1). 
Western blot analysis with mouse anti-MIF antibody identi-
fied both proteins as MIF with molecular weights of about 12 
kDa (Fig. 2). Both forms manifested the same enzymatic ac-
tivity with D-dopachrome, /»-hydroxyphenylpyruvate and phe-
nylpyruvate as substrates. We have at present no data permit-
ting interpretation or conclusions regarding the observed two 
p / forms of MIF. 
The finding that MIF isolated from bovine lens is a phenyl-
pyruvate tautomerase was confirmed in studies of human re-
Table 1 
Amino acid composition (mol %) of two forms of bovine MIF with 
different pi values 
p/8.0 p/7.7 
Asx 
Thr 
Ser 
Glx 
Pro 
Gly 
Ala 
Cys 
Val 
Met 
lie 
Leu 
Tyr 
Phe 
His 
Lys 
Arg 
9.81 
5.31 
8.97 
8.17 
6.04 
9.32 
9.14 
2.99 
6.51 
2.52 
5.42 
10.94 
2.55 
3.57 
1.49 
2.57 
4.69 
9.73 
5.39 
9.07 
8.48 
6.19 
9.27 
8.85 
2.91 
6.32 
2.66 
5.40 
10.69 
2.68 
3.65 
1.58 
2.55 
4.58 
Tryptophan not determined. 
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Fig. 2. Western blot analysis of isolated proteins with tautomerase 
activity on p-hydroxyphenylpyruvate and phenylpyruvate. The anti-
body used was a monoclonal anti-human MIF antibody (R&D Sys-
tems). Positions of size markers are indicated and sizes given in 
kDa. A: Tautomerase of bovine lens, pi 8.5. B: Tautomerase of bo-
vine lens, pi 8.3. C: Human recombinant tautomerase, pi 8.7. D: 
Phenylpyruvate tautomerase of bovine kidney (Sigma T-6004). 
combinant MIF. Chromatofocusing of human recombinant 
MIF showed the presence of a single protein with pi of 8.1 
as determined by isoelectric focusing. Mass spectrometry of 
the human recombinant MIF protein gave a molecular mass 
of 12 353 ± 0.1%, consistent with the mass of 12 345 calculated 
from the amino acid sequence of human MIF (Fig. 3). Amino 
acid sequencing showed that the N-terminal residue was pro-
line confirming the removal of the starting formylmethionine 
of the recombinant protein. The enzymatic activity of re-
combinant human MIF was the same as that of bovine 
MIF isolated from the lens. Western blot analysis with anti-
MIF antibody showed the presence of a protein with molec-
ular weight of about 12 kDa (Fig. 2). 
A commercially available bovine phenylpyruvate tautomer-
ase (Sigma T-6004) was examined for the possible presence of 
MIF protein. SDS-PAGE of the preparation yielded several 
protein bands. The protein with p-hydroxyphenylpyruvate 
tautomerase activity was isolated as previously described for 
MIF [15]. The enzymatic activity of the isolated protein was 
the same as that isolated from the bovine lens. The purity and 
homogeneity of the protein with tautomerase activity was es-
tablished by SDS-PAGE, which showed the presence of a 
single protein of molecular weight of about 12 kDa. The N-
terminal 15 amino acid residues of the protein were identical 
to those of bovine MIF [9]. Western blot analysis of the pro-
tein isolated from the commercial phenylpyruvate tautomer-
ase preparation and of MIF from the bovine lens yielded 
identical results (Fig. 2). 
4. Discussion 
The results presented demonstrate MIF and a phenylpyru-
vate tautomerase to be identical proteins. Enzymatic catalysis 
of tautomerization of phenylpyruvate and /»-hydroxyphenyl-
pyruvate was observed in studies of the degradation of phe-
nylalanine and tyrosine more than 40 years ago [21,22]. Mech-
anistic and stereochemical studies have been performed, and 
inhibitors are known [23,24], but the phenylpyruvate tauto-
merase has not previously been isolated and sequenced and its 
biological significance has remained unknown. In conjunction 
with the abundant information already available about the 
structure of MIF [25-28] and its biologic effects [8-14], the 
present findings should prove to be of relevance in defining 
the structure and biologic importance of phenylpyruvate tau-
tomerase. Thus the phenylpyruvate tautomerase isolated is a 
87 
protein consisting of 114 amino acid residues with an N-ter-
minal proline. It contains cysteines at positions 56, 59 and 80. 
The cDNAs of man and mouse encode a protein of 115 amino 
acid residues, and homology between the species is pro-
nounced. The human and murine genes are small, consisting 
of three exons contained within 1 kbp of genomic DNA 
[19,29]. 
A second protein homologous to MIF has recently been 
described. An enzyme which catalyzes the conversion of D-
dopachrome to 5,6-dihydroxyindole was isolated from rat liv-
er [17], and shown to share 27% of its amino acids with rat 
MIF [30]. A human cDNA encoding a protein with high 
homology to the rat protein was used to produce a recombi-
nant human protein which had 34% identity with human MIF 
(Fig. 3). The rat protein as well as the recombinant human 
protein have been shown to possess phenylpyruvate tautomer-
ase activity with p-hydroxyphenylpyruvate and phenylpyru-
vate as substrates (Thelin et al., unpublished observations). 
We suggest phenylpyruvate tautomerase I as the enzyme 
name for MIF, and the name phenylpyruvate tautomerase 
II for the second protein homologous to MIF. Phenylpyru-
vate tautomerase II has been found in all tissues examined in 
several species [17], and the protein has recently been isolated 
from human erythrocytes [31]. 
The monomer of MIF has a tertiary structure similar to 
that of another enzyme, Escherichia coli 5-carboxymethyl-2-
hydroxymuconate isomerase (CHMI) which has a low se-
quence homology to MIF [25,26]. The quaternary architecture 
of the MIF crystal is strikingly similar to the crystal of 
CHMI, and also to the crystal of 4-oxalocrotonate tautomer-
ase (4-OT) isolated from Pseudomonas putida [25,26,32-34]. 
CHMI and 4-OT are involved in the catabolism of products 
formed by the cleavage of aromatic rings and catalyze the 
tautomerization of such products in the degradation pathway 
to the intermediates in the citric acid cycle. The N-terminal 
proline of 4-OT is responsible for the catalytic function of this 
enzyme [33], and the N-terminal proline of CHMI seems also 
to be of catalytic importance [32]. MIF and phenylpyruvate 
tautomerase II both have proline as N-terminal amino acid 
residue, though the functional significance of this proline has 
yet to be demonstrated. 
In this study the macrophage migration inhibitory factor 
MIF has been identified as a phenylpyruvate tautomerase 
with phenylpyruvate and /»-hydroxyphenylpyruvate as sub-
strates. These substrates are directly involved in the metabo-
lism of phenylalanine and tyrosine. The relationship between 
the enzymatic function of MIF and its previously reported 
biological activities may yield insight into the mechanism of 
action of this extensively studied cytokine. However, the 
measured Km values are high in comparison with reported 
MIF 1 H I^VWIIWEEASVEK3FLSELT03I^ QMGKPPQYIAVHVVHD3LMAP3 50 
I I I I I I I I I I I I I I I I 
PPT I I 1 PFT ,ra~ rmxTT .ramnrewj ,KTOT PAAAACTT rcKPArnwMnvRpnr AMAT fi 50 
51 GSSEPCm£SIHSIGraGGA.gsiRSïSKIi03I«ŒELRISPEfWYINYY 99 
II MM I III I I III I I I II I 
51 GSIEPC^I£ISSIGWCTAEINRSHSAHFFEF1.TKELAIJ33DRILIEFF 100 
100 IMNAASVGWNNSIFA 114 
101 PIESMJIGKIGTOMrFL 117 
Fig. 3. Alignment of the amino acid sequences of human MIF and 
of human recombinant phenylpyruvate tautomerase II (PPT II), us-
ing the BestFit program [37]. 
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normal concentrations of /»-hydroxyphenylpyruvate [35] and it 
is possible that the catalytic effect on tautomerization of phe-
nylpyruvates is unrelated to other biological effects of M I F . 
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